1. Search Result
Search Result
Results for "

amyloid-β protein

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Fluorescent Dye

6

Peptides

3

Inhibitory Antibodies

6

Natural
Products

9

Recombinant Proteins

1

Isotope-Labeled Compounds

4

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0931
    Santacruzamate A
    10+ Cited Publications

    CAY-10683

    HDAC Amyloid-β Neurological Disease Cancer
    Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .
    Santacruzamate A
  • HY-P990011

    Amyloid-β Neurological Disease
    Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein.
    Sabirnetug
  • HY-14537

    Dimebolin dihydrochloride

    Amyloid-β Histamine Receptor Adrenergic Receptor 5-HT Receptor Autophagy Neurological Disease Endocrinology
    Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β () secretion.
    Latrepirdine dihydrochloride
  • HY-N0931R

    CAY-10683 (Standard)

    Reference Standards HDAC Amyloid-β Neurological Disease Cancer
    Santacruzamate A (Standard) is the analytical standard of Santacruzamate A. This product is intended for research and analytical applications. Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research[1][2].
    Santacruzamate A (Standard)
  • HY-P10613

    Amyloid-β Neurological Disease
    RERMS are bioactive peptides produced from the active regions of amyloid-β and A4 protein precursors that promote fibroblast growth and can be used in the study of neurodegenerative diseases .
    RERMS
  • HY-14862

    Dimebolin; Dimebone

    Amyloid-β Histamine Receptor Adrenergic Receptor 5-HT Receptor Autophagy Endocrinology
    Latrepirdine is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β () secretion.
    Latrepirdine
  • HY-167843

    Akt PI3K Autophagy Neurological Disease
    Alborixin is an inhibitor of the PI3K-AKT pathway that induces autophagy. It promotes the clearance of intracellular and extracellular amyloid-β by upregulating autophagy-related proteins (such as BECN1, ATG5, ATG7) and enhancing lysosomal activity, thereby reducing amyloid-β-mediated neurotoxicity. Alborixin shows potential for research in Alzheimer's disease .
    Alborixin
  • HY-P2551

    Amyloid-β Neurological Disease
    Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .
    Biotin-β-Amyloid (17-40)
  • HY-103538

    Amyloid-β Neurological Disease
    JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursor protein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor .
    JLK-6
  • HY-14537R

    Amyloid-β Histamine Receptor Adrenergic Receptor 5-HT Receptor Autophagy Neurological Disease Endocrinology
    Latrepirdine (dihydrochloride) (Standard) is the analytical standard of Latrepirdine (dihydrochloride). This product is intended for research and analytical applications. Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β (Aβ) secretion.
    Latrepirdine dihydrochloride (Standard)
  • HY-173282

    Amyloid-β Neurological Disease
    Aβ aggregation-IN-2 (Compound 8i) is an inhibitor of amyloid-β protein (Aβ42) aggregation, showing approximately 91% inhibition of Aβ42 aggregation at 25 μM. It also exhibits Aβ42 disaggregation effects and antioxidant activity. Aβ aggregation-IN-2 can be used for research in the field of Alzheimer's disease .
    Aβ aggregation-IN-2
  • HY-130244

    Beta-secretase Neurological Disease
    BACE1-IN-5 (Compound 15) is a β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 9.1 nM, and also inhibits cellular amyloid-β (Aβ) with an IC50 of 0.82 nM. BACE1-IN-5 has a medicinal chemistry that improves hERG inhibition and P-gp efflux .
    BACE1-IN-5
  • HY-126047B

    NF-κB Amyloid-β nAChR Neurological Disease Inflammation/Immunology
    (R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist . Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment .
    (R)-(+)-Anatabine
  • HY-P991130

    Amyloid-β Neurological Disease
    Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
    Dalidnetug
  • HY-19918A

    NF-κB Amyloid-β nAChR Neurological Disease Inflammation/Immunology
    Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. Anatabine dicitrate is a potent α4β2 nAChR agonist. Anatabine dicitrate inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine dicitrate has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment .
    Anatabine dicitrate
  • HY-W010041

    α-synuclein Amyloid-β Neurological Disease
    Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .
    Scyllo-Inositol
  • HY-W707693

    Isotope-Labeled Compounds Amyloid-β α-synuclein Neurological Disease
    Scyllo-Inositol-d6 is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .
    Scyllo-Inositol-d6
  • HY-P10040

    Amyloid-β Neurological Disease
    (Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .
    (Gln22)β-Amyloid (1-40) human
  • HY-P4391

    Amyloid-β Neurological Disease
    (Asp37)-Amyloid β-Protein (1-42) is the G37D mutant of wild-type Amyloid-beta (1-42) peptide .
    (Asp37)-Amyloid β-Protein (1-42)
  • HY-159083

    Amyloid-β Neurological Disease
    DN5355 is a small molecule compound that targets amyloid β protein () and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of and tau protein and disaggregate the formed and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease .
    DN5355
  • HY-124322

    Beta-secretase Neurological Disease Inflammation/Immunology
    NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E .
    NB-360
  • HY-D1443

    (trans,trans)-1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene

    Amyloid-β Others
    BSB is a Congo red-derived fluorescent probe. BSB binds not only to extracellular amyloid β protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins. BSB acts as a prototype imaging agent for Alzheimer's disease .
    BSB
  • HY-W117986

    Amyloid-β Neurological Disease
    Aβ aggregation-IN-1 (Compound 1b) is an amyloid-beta precursor protein inhibitor. Aβ aggregation-IN-1 inhibits amyloid-beta aggregation and disaggregation of fibrillogenesis with IC50 values of 3.92 and 7.19 M, respectively. Aβ aggregation-IN-1 also inhibits malondialdehyde formation, augments the intracellular reduced glutathione (GSH) levals and inhibits caspase 3 in neuronal cells .
    Aβ aggregation-IN-1
  • HY-N13742

    Dihydrohonokiol

    GABA Receptor Neurological Disease
    Dihydrohonokiol B (Dihydrohonokiol) is an anxiolytic agent. Dihydrohonokiol B can reduce the neurotoxicity induced by amyloid β protein by stimulating the GABAC receptor. Dihydrohonokiol B can be used in the research of neurodegenerative diseases such as Alzheimer's disease .
    Dihydrohonokiol B
  • HY-P4885

    AβpE3-40

    Amyloid-β Neurological Disease
    Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice .
    Glp-amyloid-β (3-40) peptide (human)
  • HY-176439

    Amyloid-β Cholinesterase (ChE) Neurological Disease
    AChE-IN-88 (Compound 26) is a novel pyridazine derivative. AChE-IN-88 is an orally active multi-target ligand for Alzheimer's disease (AD) that inhibits both acetylcholinesterase (AChE) and amyloid β protein () aggregation (pIC50: 7.16) .
    AChE-IN-88
  • HY-129133

    Drug Isomer Others
    cis-Miyabenol C is an isomer of the resveratrol trimer Miyabenol C, which can be isolated from grape herbs. Miyabenol C is an inhibitor of β-amyloid (Aβ) and amyloid β precursor protein (APP) in Alzheimer's disease model mice, and inhibit β-secretase activity without changing the protein level of β-secretase BACE1 .
    cis-Miyabenol C
  • HY-111000

    ERK Neurological Disease
    BNC-1 is an Elk-1 activator that can promote phosphorylation and activation of Elk-1 .
    BNC-1
  • HY-P990078

    LY3372993

    Amyloid-β Neurological Disease
    Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of . Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
    Remternetug
  • HY-162566

    Calcium Channel Amyloid-β Neurological Disease
    REM127 is a small molecule compound capable of modulating calcium homeostasis in cells and possesses neuroprotective effects. REM127 can restore the calcium homeostasis imbalance in cellular models caused by pathological accumulation of tau protein. REM127 can efficiently cross the blood-brain barrier, and it has the potential to rescue synaptic and cognitive deficits in Alzheimer's disease animal models, as well as to slow down the progression of amyloid-beta and tau protein pathologies. REM127 can be used for research in neurodegenerative diseases .
    REM127
  • HY-P5333A

    UB311 immunogen I acetate

    Amyloid-β Neurological Disease
    Aβ1-14-εK-KKK-MvF5 Th acetate is the acetate salt form of Aβ1-14-εK-KKK-MvF5 Th (HY-P5333). Aβ1-14-εK-KKK-MvF5 Th acetate is part of UB-311 vaccine, that targets the amyloid-beta (Aβ) protein, and ameliorates the Alzheimer’s disease .
    Aβ1-14-εK-KKK-MvF5 Th acetate
  • HY-158978

    Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC50=0.14 μM), butyrylcholinesterase (BChE, IC50=11.6 μM), monoamine oxidase B (MAO B, IC50=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .
    Multitarget AD inhibitor-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: